Regeneron Pharmaceuticals (REGN) 503.92 $REGN
Plenty of Good News -- If You Look
at The Street - Fri Oct 09, 2:13PM CDT
Not all growth is hated today.
AMZN: 539.80 (+6.64), BIIB: 269.16 (-10.72), MCK: 189.95 (+3.66), DAL: 47.21 (+1.25), UNH: 119.27 (+3.19), GOOG: 643.61 (+4.45), UAL: 55.71 (+3.45), WWAV: 43.82 (+2.11), AGN: 274.84 (-1.32), WDAY: 77.57 (+1.71), DPZ: 105.38 (+2.74), TEVA: 58.96 (-0.28), GOOGL: 671.24 (+4.24), ULTA: 165.80 (+1.86), REGN: 503.92 (+12.71)
Stock Market News for October 08, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session in the green boosted by gains in biotechnology companies
KMI: 32.35 (-0.33), BIIB: 269.16 (-10.72), MON: 89.70 (+0.45), COP: 56.10 (-0.18), AMGN: 149.59 (-0.31), BA: 139.70 (+0.66), CELG: 117.38 (-0.59), LYB: 95.45 (-2.05), GILD: 100.65 (-0.16), DD: 56.18 (+0.05), CVX: 89.57 (-0.34), DOW: 47.08 (-0.71), REGN: 503.92 (+12.71), ECL: 120.54 (+0.01), YUM: 70.25 (+2.79)
Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015
PR Newswire - Thu Oct 08, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2015 financial and operating results on Wednesday, November 4, 2015, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 503.92 (+12.71)
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), ACOR: 29.89 (-0.22), FOLD: 7.58 (+0.71), REGN: 503.92 (+12.71)
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 3:48PM CDT
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 41.89 (+0.73), ESRX: 82.72 (+0.01), AMGN: 149.59 (-0.31), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
Arpita Dutt - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Amgen (AMGN) and Regeneron (REGN) should benefit from Express Scripts' decision to place both their PCSK9 inhibitors on its National Preferred Formulary.
BIIB: 269.16 (-10.72), ONCE: 49.30 (+1.86), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), ACOR: 29.89 (-0.22), FOLD: 7.58 (+0.71), REGN: 503.92 (+12.71)
Cholesterol Busters Will Be Cheaper but Remain Top Sellers
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 07, 11:02AM CDT
Image source: Flickr user stockmonkeys.com. Pharmacy benefit manager Express Scripts runs drug programs for major health insurers and self-insured employers and that means that it's faced with the tough task of negotiating prices for new drugs,...
ESRX: 82.72 (+0.01), AMGN: 149.59 (-0.31), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 23.86 (+0.39), JNJ: 95.37 (+0.29), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), REGN: 503.92 (+12.71), CELGZ: 1.74 (+0.04)
Express Scripts to cover pricey new cholesterol treatments
By TOM MURPHY - AP - Tue Oct 06, 7:32PM CDT
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol but raise concern over prices that can top $14,000 a year.
ESRX: 82.72 (+0.01), UNH: 119.27 (+3.19), AMGN: 149.59 (-0.31), REGN: 503.92 (+12.71)
Business Highlights
By The Associated Press - AP - Tue Oct 06, 5:14PM CDT
___
AMGN: 149.59 (-0.31), MSFT: 47.11 (-0.34), AAPL: 112.12 (+2.62), REGN: 503.92 (+12.71), PEP: 99.47 (+0.50)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 2.82% Sell Off
Comtex SmarTrend(R) - Tue Oct 06, 4:00PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $448.10 to a high of $476.89. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $452.15 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 503.92 (+12.71)
Illumina (ILMN) Shares Tumble on Weak Outlook for Sales
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 3:20PM CDT
Illumina Inc. (ILMN) shares plunged more than 15% in after-hours trading yesterday
PACB: 8.07 (+0.56), ILMN: 147.77 (+7.40), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71)
Biotech stocks fall on trade deal and drug price scrutiny
By MARLEY JAY - AP - Tue Oct 06, 3:11PM CDT
NEW YORK (AP) — Biotech stocks slipped Tuesday on concerns about patent protection overseas and on continued scrutiny of the cost of some medications.
VRTX: 110.00 (+0.97), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), REGN: 503.92 (+12.71), MS: 32.72 (-0.27), CELG: 117.38 (-0.59)
Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?
Brian Feroldi, The Motley Fool - Motley Fool - Tue Oct 06, 12:17PM CDT
Photo by CDC Global via Flickr Creative Commons. Biotech behemoth Regeneron Pharmaceuticals has been on a roll recently, thanks in large part to Eylea, the company's blockbuster wet age-related macular degeneration and macular edema drug....
JNJ: 95.37 (+0.29), INO: 6.16 (+0.20), NVAX: 8.04 (+0.43), MRK: 50.95 (-0.07), NLNK: 34.31 (+1.42), GSK: 40.22 (+0.06), REGN: 503.92 (+12.71)
Gilead's Letairis Gets FDA Nod in Combination with Adcirca
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 4:00PM CDT
Gilead Sciences, Inc. (GILD) announced that the FDA has approved Letairis in combination with Eli Lilly and Company's (LLY) Adcirca for PAH.
GILD: 100.65 (-0.16), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), REGN: 503.92 (+12.71)
Illumina Poised on Product Innovation, Global Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 3:55PM CDT
On Oct 2, 2015, we issued an updated research report on Illumina Inc. (ILMN).
ILMN: 147.77 (+7.40), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71), XLRN: 24.08 (-0.18)
DBV Technologies Reveals Positive Data on Viaskin Peanut
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 1:40PM CDT
DBV Technologies (DBVT) announced top-line results from the OLFUS study on Viaskin Peanut for the treatment of patients allergic to peanuts.
DBVT: 34.82 (-0.18), EBS: 30.49 (+0.77), NVET: 3.64 (-0.10), REGN: 503.92 (+12.71)
Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 10:40AM CDT
Merck (MRK) announced that its anti-programmed death receptor-1 therapy, Keytruda, has been approved by the FDA for the treatment of metastatic non-small cell lung cancer.
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71)
Plenty of Good News -- If You Look
at The Street - Fri Oct 09, 2:13PM CDT
Not all growth is hated today.
AMZN: 539.80 (+6.64), BIIB: 269.16 (-10.72), MCK: 189.95 (+3.66), DAL: 47.21 (+1.25), UNH: 119.27 (+3.19), GOOG: 643.61 (+4.45), UAL: 55.71 (+3.45), WWAV: 43.82 (+2.11), AGN: 274.84 (-1.32), WDAY: 77.57 (+1.71), DPZ: 105.38 (+2.74), TEVA: 58.96 (-0.28), GOOGL: 671.24 (+4.24), ULTA: 165.80 (+1.86), REGN: 503.92 (+12.71)
Stock Market News for October 08, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session in the green boosted by gains in biotechnology companies
KMI: 32.35 (-0.33), BIIB: 269.16 (-10.72), MON: 89.70 (+0.45), COP: 56.10 (-0.18), AMGN: 149.59 (-0.31), BA: 139.70 (+0.66), CELG: 117.38 (-0.59), LYB: 95.45 (-2.05), GILD: 100.65 (-0.16), DD: 56.18 (+0.05), CVX: 89.57 (-0.34), DOW: 47.08 (-0.71), REGN: 503.92 (+12.71), ECL: 120.54 (+0.01), YUM: 70.25 (+2.79)
Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015
PR Newswire - Thu Oct 08, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2015 financial and operating results on Wednesday, November 4, 2015, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN: 503.92 (+12.71)
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), ACOR: 29.89 (-0.22), FOLD: 7.58 (+0.71), REGN: 503.92 (+12.71)
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 3:48PM CDT
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 41.89 (+0.73), ESRX: 82.72 (+0.01), AMGN: 149.59 (-0.31), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
Arpita Dutt - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Amgen (AMGN) and Regeneron (REGN) should benefit from Express Scripts' decision to place both their PCSK9 inhibitors on its National Preferred Formulary.
BIIB: 269.16 (-10.72), ONCE: 49.30 (+1.86), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), ACOR: 29.89 (-0.22), FOLD: 7.58 (+0.71), REGN: 503.92 (+12.71)
Cholesterol Busters Will Be Cheaper but Remain Top Sellers
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 07, 11:02AM CDT
Image source: Flickr user stockmonkeys.com. Pharmacy benefit manager Express Scripts runs drug programs for major health insurers and self-insured employers and that means that it's faced with the tough task of negotiating prices for new drugs,...
ESRX: 82.72 (+0.01), AMGN: 149.59 (-0.31), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 23.86 (+0.39), JNJ: 95.37 (+0.29), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), REGN: 503.92 (+12.71), CELGZ: 1.74 (+0.04)
Express Scripts to cover pricey new cholesterol treatments
By TOM MURPHY - AP - Tue Oct 06, 7:32PM CDT
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol but raise concern over prices that can top $14,000 a year.
ESRX: 82.72 (+0.01), UNH: 119.27 (+3.19), AMGN: 149.59 (-0.31), REGN: 503.92 (+12.71)
Business Highlights
By The Associated Press - AP - Tue Oct 06, 5:14PM CDT
___
AMGN: 149.59 (-0.31), MSFT: 47.11 (-0.34), AAPL: 112.12 (+2.62), REGN: 503.92 (+12.71), PEP: 99.47 (+0.50)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 2.82% Sell Off
Comtex SmarTrend(R) - Tue Oct 06, 4:00PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $448.10 to a high of $476.89. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $452.15 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 503.92 (+12.71)
Illumina (ILMN) Shares Tumble on Weak Outlook for Sales
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 3:20PM CDT
Illumina Inc. (ILMN) shares plunged more than 15% in after-hours trading yesterday
PACB: 8.07 (+0.56), ILMN: 147.77 (+7.40), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71)
Biotech stocks fall on trade deal and drug price scrutiny
By MARLEY JAY - AP - Tue Oct 06, 3:11PM CDT
NEW YORK (AP) — Biotech stocks slipped Tuesday on concerns about patent protection overseas and on continued scrutiny of the cost of some medications.
VRTX: 110.00 (+0.97), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), REGN: 503.92 (+12.71), MS: 32.72 (-0.27), CELG: 117.38 (-0.59)
Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?
Brian Feroldi, The Motley Fool - Motley Fool - Tue Oct 06, 12:17PM CDT
Photo by CDC Global via Flickr Creative Commons. Biotech behemoth Regeneron Pharmaceuticals has been on a roll recently, thanks in large part to Eylea, the company's blockbuster wet age-related macular degeneration and macular edema drug....
JNJ: 95.37 (+0.29), INO: 6.16 (+0.20), NVAX: 8.04 (+0.43), MRK: 50.95 (-0.07), NLNK: 34.31 (+1.42), GSK: 40.22 (+0.06), REGN: 503.92 (+12.71)
Gilead's Letairis Gets FDA Nod in Combination with Adcirca
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 4:00PM CDT
Gilead Sciences, Inc. (GILD) announced that the FDA has approved Letairis in combination with Eli Lilly and Company's (LLY) Adcirca for PAH.
GILD: 100.65 (-0.16), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), REGN: 503.92 (+12.71)
Illumina Poised on Product Innovation, Global Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 3:55PM CDT
On Oct 2, 2015, we issued an updated research report on Illumina Inc. (ILMN).
ILMN: 147.77 (+7.40), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71), XLRN: 24.08 (-0.18)
DBV Technologies Reveals Positive Data on Viaskin Peanut
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 1:40PM CDT
DBV Technologies (DBVT) announced top-line results from the OLFUS study on Viaskin Peanut for the treatment of patients allergic to peanuts.
DBVT: 34.82 (-0.18), EBS: 30.49 (+0.77), NVET: 3.64 (-0.10), REGN: 503.92 (+12.71)
Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 10:40AM CDT
Merck (MRK) announced that its anti-programmed death receptor-1 therapy, Keytruda, has been approved by the FDA for the treatment of metastatic non-small cell lung cancer.
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93), ANIK: 33.46 (+0.29), REGN: 503.92 (+12.71)
